Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.680
-0.040 (-2.33%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Cardiff Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cardiff Oncology stock have an average target of 9.63, with a low estimate of 3.50 and a high estimate of 19. The average target predicts an increase of 473.21% from the current stock price of 1.68.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 25, 2026.
Analyst Ratings
The average analyst rating for Cardiff Oncology stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +257.14% | Feb 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +495.24% | Jan 28, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $10 | Strong Buy | Maintains | $18 → $10 | +495.24% | Aug 6, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +1,030.95% | Jul 8, 2025 |
| Jefferies | Jefferies | Hold Initiates $3.5 | Hold | Initiates | $3.5 | +108.33% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
408.72K
from 593.00K
Decreased by -31.08%
Revenue Next Year
251.36K
from 408.72K
Decreased by -38.50%
EPS This Year
-0.60
from -0.69
EPS Next Year
-0.79
from -0.60
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 729,750 | 761,250 | ||||||
| Avg | 408,724 | 251,359 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 23.1% | 86.3% | ||||||
| Avg | -31.1% | -38.5% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.39 | -0.62 | ||||||
| Avg | -0.60 | -0.79 | ||||||
| Low | -0.80 | -1.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.